Vaxcyte, Inc. (PCVX)
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,325 shares of the company's stock after buying an additional 13,617 shares during the period. Bridgefront Capital
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte: Financial Durability And The Case For Disruption
Vaxcyte is positioned to disrupt the pneumococcal vaccine market with its engineered VAX-31, overcoming carrier suppression limitations faced by incumbents. PCVX's $2.7B cash position supports an aggressive Phase 3 program, with a projected runway through 2028, mitigating financing and execution risks. VAX-31 targets 95% of U.S. adult IPD strains, aiming for best-in-class breadth and efficacy, with pivotal Phase 3 OPUS trial data expected in Q4 2026.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's PFE Prevnar 20 (PCV20) in healthy infants.
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines.
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
